2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, APL, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5189 Mitoxantrone hydrochloride liposome and cytarabine combined with venetoclax as frontline induction therapy for newly diagnosed young adults with acute myeloid leukemia: A phase 2, single-arm, multicenter study

Hongfei Wu, MD, PhD, Shuhao Mei2, Hao Ai3, Zhengrong Liu4, Qian Wang5, Ge Liu6, Lu Liu7, Guang Tang8, Xiaojing Ren9, Yanliang Bai, PhD10, Zhanfang Wang11, Qinglin Song12, Dai Zhang13, Xiaojie Liu14, Xiaoqing Zhang15, Yanzhen Wang16, Yuxin Du17, Honggang Guo18, Xiaoyan Hou19, Hongxia Wang20, Qingsong Yin, PhD21
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 Xuchang Central Hospital, Xuchang, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 Anyang City People's Hospital, Anyang, China
5 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
6 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
7 Xuchang Central Hospital, Xuchang, China
8 Anyang District Hospital, Anyang, China
9 Anyang City People's Hospital, Anyang, China
10 Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, China
11 Pingdingshan First People's Hospital, Pingdingshan, China
12 Jiaozuo People's Hospital, Jiaozuo, China
13 Xuchang Central Hospital, Xuchang, China
14 Anyang City People's Hospital, Anyang, China
15 Xuchang Central Hospital, Xuchang, China
16 Anyang City People's Hospital, Anyang, China
17 Anyang District Hospital, Anyang, China
18 Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, China
19 Pingdingshan First People's Hospital, Pingdingshan, China
20 Jiaozuo People's Hospital, Jiaozuo, China
21 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Background
For fit patients with de novo acute myeloid leukemia (AML), the conventional “7+3” induction regimen remains the standard first-line intensive chemotherapy, yielding a complete remission (CR) rate of 60–80%. Nevertheless, patients with adverse-risk cytogenetic or molecular profiles achieve suboptimal therapeutic responses, and the regimen is limited by cardiotoxicity from standard anthracycline chemotherapy. Venetoclax combined with HAM lacks the potency of intensive chemotherapy for fit AML patients. Mitoxantrone hydrochloride liposome (Lipo-MIT), a novel anthracycline agent, exhibits potent antileukemic efficacy and minimal cardiac toxicity. To improve outcomes in younger newly diagnosed AML, we prospectively evaluated the efficacy and safety of Lipo-MIT, cytarabine, and venetoclax (MAV).
Methods
This prospective, single-arm, multicenter phase 2 study (ChiCTR2600129103) enrolled patients aged 18–65 years with newly diagnosed AML. All diagnoses were confirmed in accordance with the 2022 World Health Organization (WHO) criteria. All eligible patients received a MAV induction regimen consisting of Lipo-MIT (24 mg/m² intravenously on day 1), cytarabine (100 mg/m² intravenously daily on days 1-5), and oral venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-7), with a maximum of two induction cycles. Consolidation therapy comprised 3-4 cycles of intermediate-dose cytarabine (1.5 g/m² every 12 hours on days 1–3), with at least one cycle in combination with venetoclax (400 mg daily on days 1–7). Maintenance therapy consisted of venetoclax plus azacitidine for 4 to 12 cycles. The primary endpoint was the composite complete remission rate (CRc: CR plus complete remission with incomplete blood count recovery) after induction treatment. Secondary endpoints included measurable residual disease (MRD) negativity rate, event-free survival (EFS), overall survival (OS), and safety.
Results
Between Aug 2025 and Jul 2026, 25 patients were enrolled across seven centers (median age 53 years; range 31-62), with 60% male. Based on the 2022 European LeukemiaNet (ELN) criteria, 24.0% (6/25) of patients had favorable-risk, 8.0% (2/25) intermediate-risk, and 68.0% (17/25) adverse-risk disease. Notably, 3 cases (12.0%) presented with TP53 mutations. After one induction cycle, the CRc rate was 88.0% (22/25), and the MRD-negative rate was 86.4% (19/22). CRc rates for the favorable-, intermediate-, and adverse-risk subgroups were 100.00%, 100.00%, and 82.4%, respectively. MRD-negative rates were 83.3%, 100.00%, and 85.7%, respectively. Patients who achieved partial remission (PR) received the second cycle of induction treatment. Of the 3 PR patients, 2 in the adverse-risk group underwent re-induction and achieved CR with MRD negativity. The cumulative CRc rate reached 96.0% (24/25), with an MRD-negative rate of 83.3% (20/24) after induction treatment. Subsequently, one cycle of intermediate-dose cytarabine and venetoclax consolidation, 3 of 4 MRD-positive cases achieved MRD negativity. Notably, for TP53-mutated cases: one patient achieved CR with undetectable MRD after cycle 1 of induction, but relapsed after two cycles of consolidation; one achieved PR and subsequently attained CR with MRD negativity after cycle 2 of induction; one had no response (NR) and was withdrawn from the study. With a median follow-up of 4 months, the median EFS and OS have not yet been reached. Only one relapse was observed. The 6-month EFS rate was 89.1% (95% CI: 75.5%-100%). No treatment-related mortality was observed in this cohort. The 60-day mortality was 0%. The treatment-emergent adverse events (TEAEs) were predominantly Grade ≥3 hematologic toxicity. The common Grade ≥3 non-hematological TRAEs included febrile neutropenia (80.0%) and pulmonary infection (8.0%). No patients developed serious cardiovascular adverse events. Transfusion for red blood cells (RBC) and platelets was notably lower than those reported for historical "7+3" regimens (median RBC: 5.5 units; median platelets: 3 therapeutic doses).
Conclusion
The novel MAV regimen is an effective and well-tolerated induction regimen in newly diagnosed young adults with AML, including those with adverse-risk profiles. These findings warrant further investigation in larger, controlled trials with longer follow-up.
Fundings
Supported by Henan Clinical Research-oriented Doctor Program (HNCRD202510) and (244200510008).

Qingsong Yin, PhD: No relevant conflicts of interest to declare.